Advertisement
Australia markets open in 9 hours 58 minutes
  • ALL ORDS

    8,015.80
    +72.20 (+0.91%)
     
  • AUD/USD

    0.6644
    +0.0031 (+0.47%)
     
  • ASX 200

    7,778.10
    +77.80 (+1.01%)
     
  • OIL

    80.89
    +0.56 (+0.70%)
     
  • GOLD

    2,338.30
    +9.30 (+0.40%)
     
  • Bitcoin AUD

    97,545.56
    -506.98 (-0.52%)
     
  • CMC Crypto 200

    1,349.11
    -40.29 (-2.90%)
     

Gilead Sciences Inc's Dividend Analysis

Exploring the Sustainability and Growth of Gilead Sciences Inc's Dividends

Gilead Sciences Inc (NASDAQ:GILD) recently announced a dividend of $0.77 per share, payable on 2024-06-27, with the ex-dividend date set for 2024-06-14. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into Gilead Sciences Inc's dividend performance and assess its sustainability.

What Does Gilead Sciences Inc Do?

ADVERTISEMENT

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Gilead Sciences Inc's Dividend Analysis
Gilead Sciences Inc's Dividend Analysis

A Glimpse at Gilead Sciences Inc's Dividend History

Gilead Sciences Inc has maintained a consistent dividend payment record since 2015. Dividends are currently distributed on a quarterly basis. Below is a chart showing annual Dividends Per Share for tracking historical trends.

Gilead Sciences Inc's Dividend Analysis
Gilead Sciences Inc's Dividend Analysis

Breaking Down Gilead Sciences Inc's Dividend Yield and Growth

As of today, Gilead Sciences Inc currently has a 12-month trailing dividend yield of 4.73% and a 12-month forward dividend yield of 4.84%. This suggests an expectation of increased dividend payments over the next 12 months. Over the past three years, Gilead Sciences Inc's annual dividend growth rate was 3.30%. Extended to a five-year horizon, this rate increased to 5.50% per year. Based on Gilead Sciences Inc's dividend yield and five-year growth rate, the 5-year yield on cost of Gilead Sciences Inc stock as of today is approximately 6.18%.

Gilead Sciences Inc's Dividend Analysis
Gilead Sciences Inc's Dividend Analysis

The Sustainability Question: Payout Ratio and Profitability

To assess the sustainability of the dividend, one needs to evaluate the company's payout ratio. The dividend payout ratio provides insights into the portion of earnings the company distributes as dividends. A lower ratio suggests that the company retains a significant part of its earnings, thereby ensuring the availability of funds for future growth and unexpected downturns. As of 2024-03-31, Gilead Sciences Inc's dividend payout ratio is 0.85, which may suggest that the company's dividend may not be sustainable. Gilead Sciences Inc's profitability rank, offers an understanding of the company's earnings prowess relative to its peers. GuruFocus ranks Gilead Sciences Inc's profitability 8 out of 10 as of 2024-03-31, suggesting good profitability prospects. The company has reported positive net income for each year over the past decade, further solidifying its high profitability.

Growth Metrics: The Future Outlook

To ensure the sustainability of dividends, a company must have robust growth metrics. Gilead Sciences Inc's growth rank of 8 out of 10 suggests that the company's growth trajectory is good relative to its competitors. Revenue is the lifeblood of any company, and Gilead Sciences Inc's revenue per share, combined with the 3-year revenue growth rate, indicates a strong revenue model. Gilead Sciences Inc's revenue has increased by approximately 3.30% per year on average, a rate that underperforms than approximately 60.13% of global competitors. The company's 3-year EPS growth rate showcases its capability to grow its earnings, a critical component for sustaining dividends in the long run. During the past three years, Gilead Sciences Inc's earnings increased by approximately 24.50% per year on average, a rate that underperforms than approximately 30.01% of global competitors. Lastly, the company's 5-year EBITDA growth rate of 4.80%, which underperforms than approximately 61.73% of global competitors.

Conclusion

In conclusion, while Gilead Sciences Inc maintains a strong dividend history with a promising yield, the sustainability of these dividends hinges on the company's profitability and growth metrics. Investors should closely monitor the payout ratio and growth indicators to gauge future performance. For those seeking to diversify their portfolio with high-dividend yield stocks, GuruFocus Premium offers a comprehensive High Dividend Yield Screener.

This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.

This article first appeared on GuruFocus.